Key Details
Price
$41.34Annual ROE
-7.02%Beta
1.64Events Calendar
Next earnings date:
Feb 21, 2025Recent quarterly earnings:
Nov 6, 2024Recent annual earnings:
Feb 22, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
VCYT is gaining shares due to the strength of its Afirma and Decipher tests.
Veracyte's progress with key drivers and the strength in its diagnostics tests bring optimism to investors.
This Analyst Blog features McKesson, Doximity, and Veracyte.
MASI, PEN, and VCYT from the Zacks Medical Instruments sector are good investment options due to their use of genAI, strategic growth, and solid financial health. However, challenges like geopolitical tensions and problems with wages and supplies could affect their future performance.
Artisan Partners, an investment management firm, published its investor letter for the Artisan Small Cap Fund for the third quarter of 2024. You can download the letter here. During this quarter, small cap stocks performed well, especially in July when the Russell 2000 Index had a return of 10.2%.
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.
Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript
Veracyte (VCYT) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.03 per share a year ago.
In this ROBO Global Artificial Intelligence Index spotlight, we focus on Veracyte (VCYT). The index underlies the $137 million ROBO Global Artificial Intelligence ETF (THNQ).
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2024 after the close of market on Wednesday, November 6, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and.
FAQ
- What is the ticker symbol for Veracyte?
- Does Veracyte pay dividends?
- What sector is Veracyte in?
- What industry is Veracyte in?
- What country is Veracyte based in?
- When did Veracyte go public?
- Is Veracyte in the S&P 500?
- Is Veracyte in the NASDAQ 100?
- Is Veracyte in the Dow Jones?
- When was Veracyte's last earnings report?
- When does Veracyte report earnings?
- Should I buy Veracyte stock now?